supported by the National Key Research and Development Program of China(2021YFE0114300);the National Key Basic Research Program of China(973 Program)(2014CB541603);the National High Technology Research and Development Program of China(863 Program)(2013AA020106);the National Natural Science Foundation of China(82171475,82170799)。
Recently,bispecific T-cell engagers(BiTEs)and chimeric antigen receptor-modified T cells(CAR-Ts)have been shown to have high therapeutic efficacy in hematological tumors.CD87 is highly expressed in solid tumors with a...
Background: The urokinase-type plasminogen activator system which consists of a proteinase (the urokinase-type plasminogen activator, uPA), a receptor (the urokinase-type plasminogen activator receptor uPAR or CD87) a...